Project coordinator, Matteo Negro, recently participated in the 7th International Congress on Biophotonics (ICOB 2024) held in Jena, Germany, from March 3 to March 7, 2024. This interdisciplinary event brought together leading figures in biophotonics, including researchers, technologists, industry representatives, medical professionals, and policymakers, to discuss the latest developments and future trends in this dynamic field.
At ICOB 2024, CRI had the opportunity to present its cutting-edge broadband stimulated Raman microscopy technology. Matteo Negro, CEO of CRI and coordinator of the CHARM project, delivered a talk titled “Broadband Coherent Raman Platform for Stimulated Raman Histology,” where he highlighted the potential of CRI’s technology to transform histopathology. This platform offers high-speed, label-free imaging that can significantly enhance cancer diagnostics by providing pathologists with rapid, accurate information for better decision-making.
Reflecting on the event, Matteo Negro emphasized the importance of such gatherings for fostering collaboration and innovation. “ICOB 2024 was an incredible opportunity to showcase our unique technology and discuss its impact on histopathology. It was also invaluable for exchanging ideas on advancing biophotonics technologies into clinical practice,” he said.
Matteo also noted that the conference allowed CRI to engage closely with Universitätsklinikum Jena, another key partner in the CHARM project, further strengthening their collaboration and aligning their efforts to push biophotonics into real-world applications.
Participating in ICOB 2024 was particularly important for CHARM, as it allowed the team to network with key stakeholders in biophotonics and stay informed about the latest advancements. Engaging with experts and potential collaborators helps CHARM refine its technologies to better meet the needs of the medical community and align with ongoing innovations in the field.